Its values, its interview process and the questions it asks, in short episodes. Listen on a walk, then practice.
10 episodes1 free to try
No subscription needed
This is the operational module — the actual mechanics of the BMS behavioral interview. Process, structure, timeline, the specific behavioral questions reported by candidates, and how to map your stories to BMS values. This is the practical "Monday morning" episode the candidate listens to before every interview.
Chris Boerner became BMS's CEO in November 2023 and Chairman in April 2024. He inherited a company at a strategic inflection — Eliquis cliff approaching, Caforio-era legacy of expanded ESG and inclusion priorities, and a pipeline that needed urgent reinforcement. Understanding Boerner's leadership style and stated cultural priorities helps candidates calibrate every behavioral answer to what BMS leadership actually values today.
BMS is in the middle of one of the larger restructuring waves in big pharma. Candidates need to be aware of this — both to ask informed questions and to demonstrate they understand the operating environment they're walking into. This module covers the Strategic Productivity Initiative, the layoffs since 2024, and how to discuss the situation maturely in an interview.
Cell therapy is one of BMS's most strategic — and most operationally complex — businesses. The Devens, MA campus is the operational symbol of that bet. Candidates interviewing for manufacturing, supply chain, quality, regulatory, and even commercial roles in cell therapy need to understand the Devens story, the Breyanzi/Abecma franchise, and the unique challenges of CAR-T manufacturing.
For candidates in tech, data science, software engineering, and AI/ML roles, BMS's technology strategy is as load-bearing as its drug pipeline. This module covers BMS's NVIDIA AI factory, the Accenture-built Workbench platform, the AI Proteins miniproteins deal, and how cross-functional teams are organized — all critical context for interviews in any technical role at BMS.
BMS's recent strategic posture is essentially "buy the science." Understanding the acquisition history — and what each deal added to the pipeline — gives candidates the strategic context to discuss BMS's moves intelligently. This module covers five key acquisitions and what they signal about BMS's future direction and how teams integrate.
Cobenfy is the most consequential single-product story at BMS — the first new mechanism for treating schizophrenia in over 70 years, the centerpiece of the $14B Karuna acquisition, and the bet that anchors much of Boerner's pipeline narrative. Candidates in neuroscience, commercial, market access, R&D, and even general roles need to be able to discuss it intelligently, including the recent ADEPT-2 setback.
This module is the working knowledge of BMS's revenue future. Candidates should leave knowing the major growth-portfolio drugs by name, what disease each one treats, what makes each strategically important, and which acquisitions brought them in. This is the operational substrate behind the patent-cliff narrative from Module 02.
The Eliquis and Opdivo patent cliffs are the single most important strategic story at BMS, and every candidate should be able to discuss them coherently. This module gives candidates a complete grasp of the financial stakes, the timeline, and how BMS is responding — turning the most-asked motivation question ("Why BMS?") into a strategic answer instead of a generic one.
This module establishes the values framework that nearly every BMS behavioral question is designed to test. Candidates who walk in knowing the six values verbatim, having a story prepared for each, and being able to articulate their own definition of each value are dramatically better positioned. BMS interviewers literally use a sheet of paper with these values mapped to behavioral prompts.